欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
“Ranibizumab给黄斑变性患者带来了希望”令人惊喜地被美国《科学》杂志评为2006年度十大科学进展之一。Ranibizumab是一种非选择性的血管内皮生长因子抗体。临床研究表明，它不仅使多数患者保持视力稳定，更有约1／3的患者视力得到改善，可有效地治疗渗出型老年性黄斑变性。但对其长期效果仍需进行深入的观察，昂贵的价格也限制了其广泛的临床应用。
英文摘要：
＂Ranibizumab bringing a ray of hope for macular degeneration patients＂ was commented as one of the top 10 scientific breakthrough of the year 2006 by Science. Ranibizumab is a recombinant humanized monoclonal anti-vascular endothelial growth factor （VEGF） antibody fragment. The recent results of two clinical trials showed that treatment with the drug ranibizumab improved the vision of roughly one-third of patients with the wet form of age-related macular degeneration （AMD） and stabilizes the condition of most of the others. However, it is necessary to perform further clinical research for evaluating its long-term efficiency. Furthermore, the expensive drug price limits its clinical wide-ranging application.
同期刊论文项目
同项目期刊论文
Role of PI3K/Akt and MEK/ERK in Mediating Hypoxia-Induced Expression of HIF-1 alpha and VEGF in Lase
Choroidal neovascularization in age-related macular degeneration depends on vascular endothelial gro
Inhibitory Efficacy of Hypoxia-inducible factor 1α Short Hairpin RNA Plasmid DNA loaded Poly (D, L-l
Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cel
Nicotine promotes contribution of bone marrow-derived cells to experimental choroidal neovasculariza
期刊信息
位置：